RETA Stock News

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback. Earnings news picked up pace during the week and served as catalysts for stock moves. Kodiak Sciences Inc. (NASDAQ: KOD ) was among the worst decliners for the week after it''s lead candidate KSI-301 could not ace a Phase 2/3 study in wet age-related macular degeneration. On the regulatory front, Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) received a complete response letter for the new drug application for bardoxolone methyl for the treatment of patients with chronic kidney disease, caused by Alport syndrome. Meanwhile, Eli Lilly & Co. (NYSE: LLY ) and partner Boehringer Ingelheim announced the Food and Drug Administration''s nod for expanding the label for Jardiance to be used for reducing the risk of death and hospitalization for all patients with heart failure.

Reata Pharmaceuticals (RETA) has lost ~4% in the post-market Friday after the company announced that the U.S

Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q4 earnings results on Monday, February 28th, before market open.The consensus EPS Estimate is -$1.93 (-54.4% Y/Y) and the…

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announce

SAN FRANCISCO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Nov. 9, 2020 - Dec. 8, 2021 Lead Plaintiff Deadline: Feb. 18, 2022 Visit: www.hbsslaw.com/investor-fraud/RETA Contact An Attorney Now: [email protected] 844-916-0895 Reata Pharmaceuticals, Inc. (RETA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements about Reata''s Phase 3 (CARDINAL) study of one of its lead product candidates, bardoxolone methyl for treatment of chronic kidney disease caused by Alport syndrome ("AS") and the related new drug … Full story available on Benzinga.com

SAN FRANCISCO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.

NEW YORK, Feb. 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), Desktop Metal, Inc. (NYSE: DM ), DocuSign, Inc. (NASDAQ: DOCU ), and Arrival SA (NASDAQ: ARVL ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) Class Period: November 14, 2016 December 8, 2021 Lead Plaintiff Deadline: February 18, 2022 The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company''s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the FDA had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) that, as a result, there was a material risk that Reata''s NDA would not be approved; and (3) that, as a result of the foregoing, Defendants'' positive statements about the Company''s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, 2021, inclusive (the “Class Period”), of the important February 18, 2022 lead plaintiff deadline .

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) alleging that the Company violated federal securities laws. This lawsuit is on behalf of persons and…

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses Exceeding $100K – RETA

NEW YORK, Feb. 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, 2021, inclusive (the Class Period), of the important February 18, 2022 lead plaintiff deadline .

SAN FRANCISCO, Feb. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.